Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,878.85 +1,634.22 (+2.50%) CMC Crypto 200
1,366.25 -7.59 (-0.55%)
SeaStar Medical Holding Corporation (ICU)
After hours:
| Previous close | 0.4020 |
| Open | 0.4050 |
| Bid | 0.3862 x 100 |
| Ask | 0.3918 x 600 |
| Day's range | 0.3824 - 0.4106 |
| 52-week range | 0.1620 - 1.7170 |
| Volume | |
| Avg. volume | 4,214,417 |
| Market cap | 28.748M |
| Beta (5Y monthly) | -0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2100 |
| Earnings date | 15 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2024 and provides a business update. “As we guided in late February, we expect initial sales in the coming weeks of Quelimmune™ Pediatric, which is approved for the tre
- GlobeNewswire
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company’s Quelimmune™ product family) as a bridgin
- GlobeNewswire
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically
